GSK poised to leap back into the oncology market with more positive belantamab mafodotin results — but BCMA rivals are swarming in behind

GlaxoSmithKline took an important step toward a key new approval Monday night, posting their second positive round of pivotal data for the BCMA-targeting multiple myeloma conjugate belantamab mafodotin (GSK2857916). And with upbeat DREAMM-2 data, they’ve filed for an approval with hopes of getting a priority review for their “breakthrough” drug candidate.